Showing 1 to 2 of 2 results


Three-Drug Combo Doubles Survival Time for Aggressive Colorectal Cancer
A late-stage trial revealed that a three-drug combination—including a standard chemotherapy drug, cetuximab, and Braftovi—doubled the survival time for colorectal cancer patients with the BRAF V600E mutation to approximately 30 months, compared to 15 months with standard chemotherapy, offering a sig...
Three-Drug Combo Doubles Survival Time for Aggressive Colorectal Cancer
A late-stage trial revealed that a three-drug combination—including a standard chemotherapy drug, cetuximab, and Braftovi—doubled the survival time for colorectal cancer patients with the BRAF V600E mutation to approximately 30 months, compared to 15 months with standard chemotherapy, offering a sig...
Progress
44% Bias Score

Breakwater Study Shows Improved Outcomes for Colorectal Cancer Patients with BRAFV600 Mutations
A new study shows that a combined therapy of chemotherapy, encorafenib, and cetuximab significantly improves outcomes for colorectal cancer patients with BRAFV600 mutations, achieving a 68.7% response rate lasting over six months compared to 34.1% with standard chemotherapy.

Breakwater Study Shows Improved Outcomes for Colorectal Cancer Patients with BRAFV600 Mutations
A new study shows that a combined therapy of chemotherapy, encorafenib, and cetuximab significantly improves outcomes for colorectal cancer patients with BRAFV600 mutations, achieving a 68.7% response rate lasting over six months compared to 34.1% with standard chemotherapy.
Progress
40% Bias Score
Showing 1 to 2 of 2 results